Excelimmune Closes $10.5M
Woburn, Mass.-based Excelimmune has closed on $10.5 million in Series B financing. The company did not disclose the names of investors, but stated Tuesday that the financing came from a syndicate of individual investors. Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies.
31 May 2011•3 mins read
